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1. Introduction 
 
Home-made psychotropic drugs and their self-administration is a major public health 
concern. In addition to the social issues, these drugs may cause serious neurological 
conditions leading to severe disabilities. The production and abuse of substances including 
methcathinone and other synthetic cathinone derivatives are becoming epidemics. Despite 
legislative restrictions and the control of cathinones, their detection and quantification is 
limited [1,2]. 
 
In several Eastern-European countries, there is increased abuse of home-brewed 
methcathinone (a.k.a. ephedrone). Chemicals and instructions for making the drug are 
easily available on the internet. This mixture contains an excessive amount of manganese as 
a byproduct of the chemical reaction and has been linked as a causative agent with an 
movement disorder with parkinsonism, early falls, speech disorders, and dystonia [3-5]. The 
neurological syndrome closely resembles “manganism”, a condition caused by 
environmental exposure to large concentrations of manganese. 
 
The main reason for the abuse of methcathinone, which is a potent psychostimulant and 
the beta-keto analog of methamphetamine, is the amphetamine-like stimulation [6]. 
Methcathinone acts as a preferential catecholamine uptake inhibitor and a dopamine 
releaser, similar to amphetamine and methamphetamine. It has a clinically similar toxicity 
profile to amphetamine including euphoria, hallucinations and motor activation [7]. In 
experiments a divergence between in vitro and in vivo properties of methcathinone has 
been noted; the drug is very selective and potent releaser of the catecholamine 
transporters in vitro, but elevates both dopamine and serotonin levels in vivo [8]. 
 
Vesicular monoamine transporter type 2 (VMAT2) is mostly located in dopaminergic nerve 
terminals and mediates the response to various dopaminergic toxins including 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) and methamphetamine [9], [10]. It is vital in 
maintaining monoamine availability for neurotransmission [11]. Both methcathinone and 
manganese are capable of interacting with VMAT2, altering its function [12]. In previous 
imaging studies with [11C]DTBZ in humans, methcathinone and manganese decreased 
striatal VMAT2 binding in heavy methamphetamine users [13]; in addition increased binding 
in early methamphetamine abstinence [9] has been reported. 
 
We aimed to reproduce the parkinsonian syndrome caused by the drug mixture in an animal 
model. We selected a chronic dosing regimen since the onset time of the clinical syndrome 
is unknown. We measured motor activity to assess the expected movement related 
symptoms, and [11C]DTBZ was used for positron emission tomography (PET) and 
autoradiographic evaluation of the dopaminergic system to detect any early alterations at 
the cellular level. Manganese accumulation in the basal ganglia was evaluated with 
magnetic resonance imaging (MRI). 
  
2. Results 
2.1 Methcathinone and manganese analysis 
The average amount of methcathinone in the 100% Test Item solution was 9.87 mg/ml 
(range 8.82 – 10.54). The average manganese content of the 100% Test Item solution was 
0.688 mg/ml. 
Manganese concentration in blood measured 24 h after the Test Item injection was 588 μg/l 
(95% CI 410 - 750). This dropped to 70 μg/l (95% CI -170 – 310, p<0.001) 48 h after the 
injection (Figure 1). 
 
2.2 Motor activity and gait analysis 
Results of the motility box testing are summarized in Table 2. Overall, the smaller Test Item 
dose had a somewhat greater stimulating effect on the animals. Exploratory activity, 
measured by time spent in the center of the box and on rear feet, was significantly 
decreased with higher drug doses. The immediate response to the drug remained unaltered 
during the whole testing period. Within the first 5-15 minutes after the injection of Test 
Item, the acute response was clearly visible. Animals in all treatment groups demonstrated 
stereotypical movements in response to the drug. No seizures were observed. 
Gait analysis testing did not demonstrate a significant decrease in stride length or any visible 
disturbance of the stepping pattern during the study period. 
 
2.3 In vivo brain uptake of [11C]DTBZ 
Representative in vivo PET images, time-radioactivity curves for striata and cerebellum, and 
striatum-to-cerebellum retention ratio curves from the in vivo PET imaging were 
determined (Figure 2). In vivo PET scans showed that [11C]DTBZ uptake in the brain peaked 
during the first minutes after the injection. The striatum-to-cerebellum ratios calculated for 
the duration of the whole dynamic scan increased in the initial phase, but only minor 
change was seen from 5 to 20 min. The maximum ratio obtained during this time frame was 
2.1±0.3 (n=3) (Figure 2). Based on these findings 10 min after injection was chosen as the 
time point for ex vivo experiments. 
 
2.4 Ex vivo [11C]DTBZ tissue counting and digital autoradiography  
In the brain, the [11C]DTBZ uptake at 10 min after injection was 3.2 ± 0.2 %ID/g in 100% Test 
Item injected mice (Group 1), and 3.7 ± 0.2 %ID/g in saline injected mice (Group 4) after 13 
weeks of injections, and 3.0 ± 0.3 %ID/g and 3.4 ± 0.1 %ID/g, respectively, after 27 weeks of 
injections. The striatum-to-cerebellum ratios calculated from the digital autoradiography 
images after 13 weeks of daily injections were 2.6 ± 0.5 for 100% Test Item injected mice 
(Group 1, n = 3) and 2.7 ± 0.5 (n = 3) for saline injected mice (Group 4, n = 4). After 27 weeks 
of injections, the ratio remained similar at 2.8 ± 0.3 (n=4) in Group 4 mice, however, the 
ratio for Group 1 mice increased to 3.6 ± 0.5 (n=3) and the difference between groups was 
statistically significant (p = 0.04) (Figures 3 and 4). 
 
  
3. Discussion 
 
The combination of methcathinone and manganese in a homemade drug mixture causes 
parkinsonian symptoms in human drug abusers after chronic administration. Both 
substances act as toxins towards the dopaminergic system and there is clear evidence of 
dopaminergic damage, while at the same time the common anti-parkinsonian treatments 
fail. We used the drug mixture in a chronic animal experiment over 27 weeks aiming to 
reproduce a similar movement disorder in animals. We used different dilutions of the Test 
Item since there is no reported dosage for animal experiments. 
 
The [11C]DTBZ is a well-established marker of VMAT2. We observed an increase of striatal 
[11C]DTBZ binding after 27 weeks of treatment. This finding is indicative of a lack in striatal 
vesicular dopamine. A similar increase of DTBZ binding was demonstrated after depleting 
dopamine with systemic administration of α-methyl-DL-tyrosine methyl ester hydrochloride 
(AMPT) and administering a single dose of amphetamine [16, 17]. Methcathinone is known 
to release dopamine from presynaptic vesicular storage and inhibit its subsequent reuptake 
from the synapse therefore leaving its binding sites available. 
 
The Test Item dosage was based on the results of a pilot experiment (unpublished data). The 
highest dose (100% Test Item) was chosen so that it would reliably produce an evident 
increase of locomotor activity. Lower concentrations were also tested to determine how the 
Test Item behaves over an extended period. Doses that were too high could attenuate 
motor activity and become lethal as shown with amphetamine [18]. Our chronic treatment 
regimen failed to reproduce the clinically evident, persistent parkinsonian syndrome with 
any of the Test Item dilutions. This is possibly due to several reasons. The amount of 
manganese and methcathinone in the mixture was evidently insufficient. In addition, the 
dosing regimen consisted only of a single injection each day. However, the acute effects of 
methcathinone on locomotor activity remained clearly visible throughout the duration of 
our experiment. 
 
A human PET study by Lee et al. in Parkinsonian patients showed that extensive loss of 
dopamine neurons is functionally compensated for by increased synthesis and release of 
dopamine from remaining dopamine neurons and by reduced uptake of dopamine into 
nerve terminals. Thus, in our study the discrepancy between motor symptoms and changes 
in DTBZ binding may result from changes in other pathways of striatal dopaminergic 
transmission not revealed by [11C]DTBZ binding [19]. 
 
Excess intake of manganese, independent of the route of administration, results in 
accumulation of the metal in basal ganglia. Studies of active drug abusers using MRI 
demonstrated increased T1 weighted signal in the globus pallidus and substantia nigra, that 
is indicative of manganese accumulation. The signal normalizes within a few months after 
cessation of manganese intake; while clinical symptoms remain unchanged [21, 21]. This 
feature has also been described in animal experiments with rhesus monkeys [22]. We 
performed an MRI scan of two Test Item treated animals (data not shown) but did not 
observe the typical T1 weighted signal increase within 24 h from the last injection despite 
relatively high doses and high blood concentrations of manganese. A possible explanation is 
either fast washout of manganese, eliminating the possibility of cellular deposits in the 
brain, or the administered amount was insufficient. Blood manganese concentrations 
measured at 24 h and 48 h after the last injection support the hypothesis of fast washout. 
 
A significant decrease in metabolic activity of the glutamatergic cells throughout the brain 
and GABA-ergic cells in the basal ganglia has been described in mice after administration of 
25 mg/kg of manganese for 21 days [23]. A resulting reduction of paw grip strength was also 
observed in this study. Another study in mice described manganese accumulation in basal 
ganglia after administration of 50 or 100 mg/kg of manganese [24]. Manganese doses 
inducing morphological and clinical changes have been markedly higher than in our study. 
 
The limitations of our study include the lack of direct measurements of striatal dopamine 
concentration. We used chronic administration of an amphetamine analog to alter striatal 
dopamine levels, but the dosage was derived from human users and could be too low for 
rodents. In humans a single small dose of amphetamine is thought to be insufficient to 
cause a loss of striatal dopamine [25]. We hypothesize that a rodent model of the persistent 
parkinsonian syndrome is nonetheless feasible by further altering the dosage and 
administration regimen of the active substances.  
 
The number of various "legal highs" with amphetamine-like psychostimulant properties is 
constantly increasing. At the same time the toxicity profiles of these substances are not well 
known and there is a lack of clinical and basic studies to explain the mechanisms of action in 
the central nervous system. Our findings indicate that chronic treatment with low doses of 
methcathinone in combination with manganese can induce changes in VMAT2 function.  
 
  
4. Materials and methods 
 
4.1 Animals and study design 
The study was planned as a chronic experiment with a total duration of 27 weeks. 
Sixty male C57B6/JRcc Hsd mice (Harlan Laboratories, The Netherlands) aged 5 weeks at the 
beginning of the study were used. Animals were randomly assigned into one of the four 
treatment groups (n = 15/group, see Table 1) and housed in smaller groups of seven to eight 
at standard room conditions with 12h/12h light/dark cycles. They had free access to food 
and water. All animals were weighed once a week. Weight loss exceeding 20% of body mass 
was considered the study termination point. 
All injections (0.3 ml) were given intraperitoneally once a day for the whole study duration. 
For the in vivo PET experiments, three male C57Bl/6N mice (aged 10 weeks) from the 
Central Animal Facility of the University of Turku were used. 
Groups were defined by the dose of methcathinone as follows: Group 1 received Test Item 
containing 100 mg of methcathinone per kilogram of body weight (100% Test Item), Group 2 
received (50 mg/kg of methcathinone (50% Test Item), Group 3 received (20 mg/kg of 
methcathinone (20% Test Item). Group 4 served as the control group and was injected with 
0.9% saline (Table 1). 
 
All applicable institutional and national guidelines for the care and use of animals were 
strictly followed at both participating institutions. The study was approved by the Estonian 
National Board of Animal Experiments and the Animal Experiment Board of the Province of 
Southern Finland. 
 
4.2 Substances 
Test Item 
The Test Item was prepared as previously described [14] to closely resemble the mixture 
injected by drug abusers. Briefly, 12 pills containing 60 mg of pseudoephedrine 
hydrochloride (Sudafed, GlaxoSmithKline Pharmaceuticals, Poland) were stripped of the 
coating layer by thorough washing. The pills were crushed and dissolved in 60 ml of boiling 
tap water. The oxidizing agent was1 g of potassium permanganate (KMnO4, Grindex Ltd, 
Latvia) and 0.45 ml of vinegar was added to complete the reaction. The solution was rapidly 
cooled to room temperature, filtered through regular filter paper to remove visible debris 
and stored at +4˚C. Dilutions were made using 0.9% saline. 
 
Methcathinone content analysis 
The Direct Analysis in Real Time (DART) method was used to measure the methcathinone 
content in the 100% Test Item. Three separately prepared samples of the mixture were 
analyzed. The system consisted of a DART ion source (Control software version 1.55, 
IonSense Inc, Saugus, MA, USA) and the Accurate Time of Fight (AccuTOF) mass 
spectrometer (JEOL JMS-T100LC, Tokyo, Japan) operating in positive-ion mode and 
controlled by “Mass Center main” software (Version 1.3.7, JEOL Ltd., Akishima, Japan). 
Helium (4.0L/min) was used as the ionization gas of the DART ion source. All measurements 
were performed with the orifice 1 voltage 15V, gas heater temperature of 400˚C, discharge 
electrode needle at 3000V, electrode voltage at 177V, and grid electrode voltage at 384V. 
Internal mass calibration was achieved using a dilute solution of polyethylene glycol (PEG) 
600 in methanol. Mass to charge ratio (m/z) range of 100-1000 was used in recording mass 
spectra. The recorded mass spectral data were processed with the Mass Center software 
(JEOL, Tokyo, Japan); background subtraction and intensity centralizing were carried out in 
peak detection. 
 
Manganese content analysis 
Manganese concentration in the 100% Test Item was analyzed using a SpectroCirosCCD 
Inductively Coupled Plasma-Atomic Emission Spectrometry (ICP-AES) (Spectro Analytical 
Instruments GmbH&Co, Kleve, Germany) as described in detail earlier [14]. Manganese 
levels in the blood samples were determined by atomic absorption spectrometry. Blood for 
testing was drawn from the left ventricle of the heart immediately after the animal was 
sacrificed. Animals from Group 1 (n=3) and Group 4 (n=4) were used. Samples were 
analyzed by electrothermal atomic absorption method (ETAAS) SpectraAA 220Z (Varian, 
Mulgrave, Australia) with Zeeman-effect background correction. Certified reference 
materials (Seronorm Trace elements Whole Blood L1 LOT MR4026 and L2 LOT 0503109) 
were used. In cases of high manganese content, 0.2 ml of blood was diluted to 1.0 ml with 
milliQ water, while, for normal levels, 0.1 ml of blood was diluted to 1.0 ml with milliQ 
water. 
 
4.3 Imaging studies 
Radiosynthesis 
The [11C]DTBZ was synthesized at the Radiopharmaceutical Chemistry Laboratory of the 
Turku PET Centre and the final product was formulated in 0.9% NaCl / 0.1 M phosphate 
buffer (3/2, v/v). The specific radioactivity of [11C]DTBZ was 307.9  228.8 MBq/nmol (n = 6, 
range from 36.7 to 623.7 MBq/nmol) at the end of synthesis. The radiochemical purity of 
the product exceeded 95% in all syntheses. 
 
In vivo PET imaging 
Dynamic in vivo PET imaging (13 frames: 5 x 60, 1 x 300, 5 x 600 s) of healthy, untreated 
C57Bl/6N mice (n=3) was performed to determine the optimal time point for subsequent ex 
vivo brain autoradiography experiments. Imaging was performed using the Inveon 
multimodality PET/CT scanner (Siemens Medical Solutions, Knoxville, TN, USA) as described 
earlier [15]. The scan started immediately after intravenous injection of [11C]DTBZ (injected 
dose 9.6 ± 4.5 MBq, injected mass 16.1 ± 15.0 ng). Striata and cerebellum were selected as 
regions of interest (ROIs) using Inveon Research Workplace Image Analysis software 
(Siemens Medical Solutions, Knoxville, TN, USA). A CT template from the same mouse and a 
co-registered general mouse brain MRI template were used as anatomical references. The 
uptake of 11C-radioactivity in the brain was evaluated as striatum-to-cerebellum ratios from 
the time-activity curves. 
 
Ex vivo [11C]DTBZ tissue counting, digital autoradiography and image analysis 
Animals from Group 1 (100% Test Item) and Group 4 (control) were used for ex vivo 
[11C]DTBZ experiments after 13 weeks (Group 1 n = 4; Group 4 n = 4) and 27 weeks of 
treatment (Group 1 n = 3; Group 4 n = 4). 
The animals were killed by CO2 inhalation 10 min after the injection of [11C]DTBZ. The 
intravenously injected radioactivity per animal was 25.4 ± 4.7 MBq (injected mass range 33 
to 580 ng). The brains were dissected, measured for radioactivity, frozen and sectioned for 
digital autoradiography as described earlier [15]. 
The obtained autoradiography images were analyzed for count density (photostimulated 
luminescence per unit area, PSL/mm2) ratios between defined ROIs for striata and 
cerebellum with a computerized image analysis program (Aida 4.22, Raytest 
Isotopenmessgeräte, GmbH, Straubenhardt, Germany). The ROIs were drawn on at least 
three different sections from every animal. Count densities for background areas were 
subtracted from each ROI value, the mean values were calculated and the striata-to-
cerebellum ratios were obtained. 
 
4.4 Locomotor activity testing 
Motility box 
Locomotor activity (evaluated as the time in locomotion and travelled distance) and 
exploratory behavior (evaluated as the time spent on rear feet and in the center of the box) 
were tested at baseline, and at 13 and 27 weeks. Six animals from each group were tested. 
Animals were placed alone into a photoelectric motility box (448 mm x 448 mm x 450 mm) 
connected to a computer (ActiMot/MoTil, TSE Technical & Scientific Equipment GmbH, 
Germany) immediately after receiving the injection of Test Item or saline. The illumination 
level of the transparent test boxes was approximately 400 lux. Data were captured for the 
first 60 min. The box center was defined as 60% of the centermost area of the floor. Group 
means were calculated for further statistical analysis. 
 
Ink test 
Ink testing was carried out every four weeks seven times during the experiment. Nine 
animals from each treatment group were included. Testing was carried out before giving the 
injections of Test Item or saline. After coating the animals’ feet with non-toxic colored ink 
(red ink for front feet and blue ink for rear feet) the mice ran along a 50 cm tunnel that was 
lined with white paper. Resulting footprints were used to measure the stride length 
between front and rear feet on both sides. Five steps were measured in each case and the 
average step length was calculated for each animal. Group means were used for statistical 
analysis. 
 
4.5 Data analysis 
Results are expressed as means and standard deviations with 95% confidence intervals. 
Statistical analysis was performed with GraphPad Prism, version 5.01 (GraphPad Software, 
San Diego, CA, USA). Manganese concentrations were analyzed by Kruskall-Wallis test and 
motility box data were analyzed by using two-way ANOVA. Autoradiography results from 
the mice treated with Test Item (Group 1) or saline (Group 4) were compared between 
groups using unpaired two-tailed Student’s t-test. The limit for statistical significance was 
set at p<0.05. 
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Figure Legends 
 
Figure 1. Blood manganese concentrations. Results for mice treated with the 100% Test 
Item (Group 1, n = 3) 24 and 48 h after the last injection at 27 weeks and Control (Group 4, n 
= 4). 
 
Figure 2. Representative in vivo PET images of a non-treated C57Bl/6N mouse (time frames 
10-20 min after [11C]DTBZ injection) from the levels of striata and cerebellum (A), and time-
radioactivity curves as percentage of injected dose/g tissue (%ID/g) obtained from VOIs 
drawn to the striata and cerebellum (B). Striata-to-cerebellum ratio curve was determined 
for the duration of the 60 min scan and it stayed constant from 5 min onwards. The 10 min 
time-point was chosen for the ex vivo brain autoradiography studies (C). 
 
Figure 3. Ex vivo autoradiography images of brain slices showing 11C-radioactivity uptake 10 
min after [11C]DTBZ injection. Left slices are from the cerebrum at the level of striatum (S) 
and cortex (CTX), and lower slices are from the cerebellum (CB). A mouse treated with 100% 
Test Item (27 wk, upper panel) and a saline treated mouse (27 wk, lower panel), Red/yellow 
color represents high uptake and blue represents low uptake of radioactivity. Color scales of 
the images are normalized to the injected dose (ID) per animal. 
 
Figure 4. Ex vivo brain autoradiography results after 13 weeks (Group 1 [treated], n = 3; 
Group 4 [control], n = 3) and 27 weeks (Group 1, n = 3; Group 4, n = 4) of treatment. 
Accumulation of 11C-radioactivity in striata (Str) compared with cerebellum (CB) 10 min after 
the [11C]DTBZ injection. 
 
  
Table 1. Description of the treatment groups and numbers of animals used for testing. 
 
  
 Group 1 Group 2 Group 3 Group 4 
 100% Test Item 50% Test Item 20% Test Item Saline 
Treatment, average substance dose 
Methcathinone (mg/kg) 98.7 49.3 19.7 - 
Manganese (mg/kg) 6.88 3.44 1.38 - 
Mean weight (g) 
Week 1 29 31 31 33 
Week 27 28 28 30 28 
Number of animals used for testing 
Group total 15 15 15 15 
Motility Box 6 6 6 6 
Gait analysis 9 9 9 9 
Ex vivo autoradiography 6 - - 7 
Brain tissue counting 7 - - 8 
Table 2. Motility box test results. Six animals from each group were tested 3 and 6 months 
after the treatment began. Results were compared with the control group (Group 4) at the 
same time point. 
 
 Distance (m) Time in center (s) Time on rear feet (s) 
 3 months 6 months 3 months 6 months 3 months 6 months 
Group 1 203.8 343.0* 3.2*** 23.5*** 142.8 58.7*** 
Group 2 241.0 395.3*** 3.0*** 49.8*** 190.5 136.2** 
Group 3 425.7*** 362.7** 23.7* 61.0* 198.0 337.5 
Group 4 209.2 214.8 77.2 138.2 318.2 384.3 
*=p<0.05; **=p<0.01; ***=p<0.001. 
 




